Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first ...
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash
Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations into the first quarter of 2026 Company is debt-free after repaying mortgage on facilities ...
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.
Tonix reports preliminary Q4 net revenue $10.1M vs $7.8M last year
The Company had approximately $98.8 million in cash and cash equivalents as of December 31, 2024. Maximize Your Portfolio with Data Driven ...
manilatimes3h
Intelligent Bio Solutions Expands with UK Partnership, Driving Global Growth Ahead of Planned U.S. Launch
UK drug testing market projected to hit $453M by 2030, positioning INBS as a scalable, cost-effective industry leader NEW YORK, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq ...